Skip to content
value.today

Glyphic Biotechnologies, Inc.

🇺🇸 New York, New York, USABiotechnologyFounded 2021
Total raised
$33 M
1 round on record
Latest round
$33 M
Feb 2024
First round on record
Feb 2024
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Glyphic Biotechnologies, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2024$33 MNo. 1$10 to $50 million

Glyphic Biotechnologies, Inc.: Raise no. 1, Feb 2024

Investors in this round

37 investors had bought by the notice of Feb 16, 2024: 37 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$33 M of $53 M offered; $20 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daniel Estandian · Executive Officer, Director
  • Joshua Yang · Executive Officer, Director
  • Craig Asher · Director
  • Jimmy Yun · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Joshua Yang, Chief Executive Officer. Newest notice filed Feb 16, 2024. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Glyphic Biotechnologies, Inc. chose not to state its revenue in its newest notice of a funding round (Feb 2024).

    SEC Form D · Feb 2024

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Feb 2024

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Glyphic Biotechnologies, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Glyphic Biotechnologies, Inc.
NameRoleNamed in
Daniel EstandianExecutive officerFeb 2024
Joshua YangExecutive officerFeb 2024
Craig AsherDirectorFeb 2024
Daniel EstandianDirectorFeb 2024
Jimmy YunDirectorFeb 2024
Joshua YangDirectorFeb 2024